A separate analysis of the SELECT population
The kidney report used SELECT data from adults with overweight or obesity and established cardiovascular disease without diabetes. It compared weekly semaglutide 2.4 mg with placebo and examined a prespecified kidney composite. This was an additional analysis within the cardiovascular trial, rather than a newly randomized kidney study. [1]
That distinction helps locate the evidence. The participants were selected for the parent trial’s clinical setting, not because they all had the same degree of chronic kidney disease. A finding in this population should not be presented as though it came from an entirely different renal population.
A small absolute difference in a defined composite
The composite occurred in 1.8% with semaglutide and 2.2% with placebo, with a hazard ratio of 0.78. It included kidney-related death, chronic kidney replacement therapy, persistent very low filtration, major persistent filtration decline or new persistent macroalbuminuria. Filtration measurements at 104 weeks also favored semaglutide. [1]
The absolute difference in the reported event proportions is 0.4 percentage points. That figure and the relative hazard estimate describe different aspects of the result. Neither should be relabeled as the percentage of people whose kidneys improved, because the endpoint counted a specified combination of adverse events.
Compare with FLOW carefully
FLOW studied a defined population with type 2 diabetes and chronic kidney disease using a different regimen and kidney-focused design. SELECT’s lack of diabetes is a meaningful difference. The two sources can broaden understanding without being pooled casually into one universal kidney claim.
Composite definitions matter too. Including an albuminuria event makes the outcome different from one restricted to kidney failure or death. A reader should examine the components before comparing hazard ratios from separate papers. A smaller number does not automatically mean a stronger treatment for every kidney outcome.
The filtration analysis at a specified week should also be distinguished from event follow-up. A laboratory difference at 104 weeks and a time-to-event estimate are not observations on the same scale. They can support a coherent picture without being combined into a single invented percentage of kidney protection.
Use the finding as part of the broader review
Ask the clinician which diagnosis and laboratory findings determine the relevance of these data to you. A consumer article cannot translate a population-level relative estimate into your personal risk or decide which treatment is appropriate. The point of reading the source is to make the clinical discussion more precise.
For the parent trial’s principal question, read SELECT cardiovascular outcomes. If a provider cites kidney protection, ask which study, population and endpoint support that phrase. A clear answer should preserve the limits of the evidence rather than treating every favorable kidney-related measurement as the same benefit.